Aspirin-exacerbated Respiratory Disease
10
0
2
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
10%
1 trials in Phase 3/4
33%
2 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (10)
Mechanisms of Dupilumab in AERD
Role of IL-5R Signaling in Non-eosinophil Upper Airway Cells in CRSwNP
Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory Disease
Effect of Celecoxib on Postoperative Analgesia and Disease Severity in AERD Patients with CRS
Therapeutic Control of Aspirin-Exacerbated Respiratory Disease With Ifetroban
Characteristics of Patients Diagnosed With NSAID Sensitivity in Thailand
Dupilumab for Aspirin-exacerbated Respiratory Disease
Effects of a High or Low Salycilate Diet on Urinary LTE4 and Clinical Features in AERD
Sleep Quality After Nasosinusal Surgery in AERD Patients
A Comparison of microRNA Samples in Patients With Nasal Polyps and Aspirin Exacerbated Respiratory Disease and Those With Nasal Polyps Only